Details of the Drug

General Information of Drug (ID: DM8TNX3)

Drug Name
Etizolam
Synonyms
Etizolam [INN:JAN]; Etizolamum [INN-Latin]; VMZUTJCNQWMAGF-UHFFFAOYSA-N; Y 7131; Y-7131; etizolam; 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 40054-69-1; 6-(o-Chlorophenyl)-8-ethyl-1-methyl-4H-s-triazolo(3,4-c)thieno(2,3-e)(1,4)-diazepine; 8-Ethyl-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine; A76XI0HL37; AHR 3219; BRN 0572740; C17H15ClN4S; Depas; NCGC00182031-01; UNII-A76XI0HL37
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Approved [1]
ATC Code
N05BA19: Etizolam
N05BA: Benzodiazepine derivatives
N05B: ANXIOLYTICS
N05: PSYCHOLEPTICS
N: NERVOUS SYSTEM
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 342.8
Logarithm of the Partition Coefficient (xlogp) 2.6
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 2,488.6 mcgh/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2.83 h [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination
The amounts of etizolam excreted was 30% in urine was 70% in feces (in a rat study) [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.4 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.16676 micromolar/kg/day [5]
Vd
The volume of distribution (Vd) of drug is 0.9 +/- 0.2 L/kg [4]
Chemical Identifiers
Formula
C17H15ClN4S
IUPAC Name
7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
Canonical SMILES
CCC1=CC2=C(S1)N3C(=NN=C3CN=C2C4=CC=CC=C4Cl)C
InChI
InChI=1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3
InChIKey
VMZUTJCNQWMAGF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3307
ChEBI ID
CHEMBL31583
CAS Number
40054-69-1
UNII
A76XI0HL37
DrugBank ID
DB09166
INTEDE ID
DR0665
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [7]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Gschwend MH, Guserle R, Erenmemisoglu A, Martin W, Tamur U, Kanzik I, Hincal AA: Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects. Arzneimittelforschung. 2007;57(6):315-9. doi: 10.1055/s-0031-1296625.
3 BDDCS applied to over 900 drugs
4 World Health Organization: Etizolam (INN) Pre-Review Report
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol. 2004 Aug;60(6):427-30.
7 Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007 Aug;32(4):333-41.
8 Etizolam (INN) Pre-Review Report.